English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 11 May 2022, 14:33 HKT/SGT
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead(TM) Programs at the TIDES USA 2022

Gaithersburg, MD, USA and Suzhou BioBay, China, May 11, 2022 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on its GalNAc-Liver-Targeting platforms and a progress report on its GalAhead(TM) technologies and programs at the TIDES USA 2022 Conference. TIDES 2022 is taking place May 9-12, 2022 at the Hynes Convention Center in Boston.

Oral Presentation Details
-- Presentation Title: mxRNA(TM): Miniaturized RNAi Triggers Composed of Single Oligonucleotides
-- Presentation Segment: Oligonucleotide Discovery, Preclinical and Clinical
-- Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
-- Time/Date: 9:00am - 9:30am ET, Thursday, May 12, 2022.
-- Location: Hynes Convention Center, Room 102

Dr. Dmitry Samarsky, Sirnaomics Chief Technology Officer, will provide an oral presentation data demonstrating mxRNA efficacy in primary hepatocytes (in vitro) and in mice (in vivo). He will also present results of a 26-week study in non-human primates conducted with the candidate molecule for Sirnaomics' frontrunner GalAhead(TM) therapeutic program, targeting coagulation Factor XI, and report on progress made with other therapeutic programs based on the GalAhead(TM) platform.

For more information about Sirnaomics' presentation, visit the event website here.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.

Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

Media (US):
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Media (China):
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com

Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
United Labs GmbH Announces the Launch of Its Next Generation NFT Project - United Bear Society  
May 16, 2022 21:00 HKT/SGT
Tam Jai International's Adjusted Profit for the Year Rises by 17.8% to HK$165.5 Million  
May 16, 2022 17:35 HKT/SGT
CITIC Telecom CPC launches SmartCLOUD(TM) Container Service to Empower Businesses for Application Development  
May 16, 2022 14:30 HKT/SGT
Fujitsu Charts Path to Purpose-driven Leadership with "Technology and Service Vision 2022"  
Monday, May 16, 2022 12:12:00 PM
Mitsubishi Shipbuilding and NYK Line Obtain Approval in Principle (AiP) from Classification Society ClassNK for Large LCO2 Carrier  
Monday, May 16, 2022 11:41:00 AM
The Lan Space Announces The Summit In Davos  
May 16, 2022 08:26 HKT/SGT
The Executive Talk: Kerry Express (Thailand) PCL (SET: KEX)  
May 16, 2022 08:00 HKT/SGT
El Salvador's Ambassador to the United States to Represent the El Salvador People at GBA's Blockchain & Sustainable Economic Growth Conference  
May 16, 2022 01:06 HKT/SGT
Solve.Care Foundation CEO Pradeep Goel to Speak about Blockchain Technology in Healthcare at GBA's Blockchain & Sustainable Economic Growth Conference  
May 16, 2022 00:01 HKT/SGT
CNERGENZ Berhad IPO Shares Oversubscribed by 40.32 Times  
May 13, 2022 19:00 HKT/SGT
More Press release >>
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575